المؤلفون: United States Agency for International Development (USAID)

المصدر: Avelox package sert. U.S. Food and Drug Admtratn. (2016). Label: Avelox (moxloxac hydrochlore) tablets. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdfTest
Bacwz AM, Self TH. onz teractns. South Med J. 1985 Jun;78(6):714-8. do 10.1097/00007611-198506000-00025.
Ball P. Moxloxac (Avelox): an 8-methoxyquolone antacterl wh enhanced potency. t J Cl Pract. 2000 Jun;54(5):329-32.
Berg A, Clary J, Hanna D, Nuermberger E, Lenaerts A, Ammerman N, Ramey M, Hartley D, Hermann D. Model-Based Meta-Analys of Relapsg Mouse Model Studs from the Cral Path to Tuberculos Drug Regens te Database. Antrob Agents Chemother. 2022 Mar 15;66(3):e0179321. do 10.1128/AAC.01793-21. Epub 2022 Jan 31.
Blumberg HM, Burman WJ, Chason RE, Daley CL, Etkd SC, Frdman LN, Fujara P, Grzemska M, Hopewell PC, eman MD, Jasmer RM, Koppaka V, Menzs R O'Brn RJ, Reves RR, Rehman LB, Sone PM, Starke JR, Vernon AA; Ameran Thorac Socty, Centers for Dease Control and Preventn and the fectus Deases Socty. Ameran Thorac Socty/Centers for Dease Control and Preventn/fectus Deases Socty of Amera: treatment of tuberculos. Am J Resp Cr Care Med. 2003 Feb 15;167(4):603-62. do 10.1164/rccm.167.4.603. No abstract avaable.
Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, ChoudhrS, Daley CL, Munsf SS, Zhao Z, Vernon A, Chason RE. Moxloxac versus ethambutol the fst 2 months of treatment for pulmonary tuberculos. Am J Resp Cr Care Med. 2006 Aug 1;174(3):331-8. do 10.1164/rccm.200603-360OC. Epub 2006 May 4.
Centers for Dease Control and Preventn. (2023, March 22). Tuberculos (TB) Treatment, Treatment for TB Dease. https://www.cdc.gov/tb/top/treatment/tbdease.htmTest
Combs DL, O'Brn RJ, Geer LJ. USPHS Tuberculos Short-Course Chemotherapy Trl 21: effecteness, toxy, and acceptaby. The report of fal results. Ann tern Med. 1990 Mar 15;112(6):397-406. do 10.7326/0003-4819-76-3-112-6-397.
Conde MB, Efron A, Loredo C, De Souza GR, Graca NP, Cezar MC, Ram M, Chaudhary MA, BhaWR, KrskAL, Chason RE. Moxloxac versus ethambutol the l treatment of tuberculos: a double-bld, randomed, controlled phase trl. Lancet. 2009 Apr 4;373(9670):1183-9. do 10.1016/S0140-6736(09)60333-0.
Donald PR, Marz JS, Dcon AH. The pharmacokets and pharmacodynams of ramp adults and chdren relatn to the dosage recommended for chdren. Tuberculos (Edb). 2011 May;91(3):196-207. do 10.1016/j.tube.2011.02.004. Epub 2011 Mar 22.
Dooley KE, Park JG, Swdells S, Allen R, Haas DW, Cramer Y, Aweeka F, Wgs Gupta A, Lak P, Qasba S, van Heeswk R, Flexner C; ACTG 5267 Study Team. Safety, toleraby, and pharmacoket teractns of the antuberculous agent TMC207 (bedaque) wh efavenz healthy volunteers: AS Clal Trls Group Study A5267. J Acqu mune Def Syndr. 2012 Apr 15;59(5):455-62. do 10.1097/QA0b013e3182410503.
Dooley KE, Blen-Semore EE, Weer M, Lu Y, Nuermberger EL, Hubbard WC, Fuchs EJ, Mel MT, Burman WJ, Dorman SE. Safety and pharmacokets of escalatg day doses of the antuberculos drug rapente healthy volunteers. Cl Pharmacol Ther. 2012 May;91(5):881-8. do 10.1038/clpt.2011.323.
Dooley KE, Kaplan R, Mwelase N, Grsztejn B, Tona E, Lacerda M, Sued O, Belonosova E, A-Khaled M, Angel K, Brown D, Sgh R, Talaro CL, Tenor AR, Keegan MR, Aboud M; ternatnal Study of Patnts wh H on Ramp G study group. Dolutegrav-based Antetroval Therapy for Patnts Cofected Wh Tuberculos and Human munodefncy Vus: A Multenter, Noncomparate, Open-label, Randomed Trl. Cl fect D. 2020 Feb 3;70(4):549-556. do 10.1093/c/c256.
Dorman SE, Goldberg S, Stout JE, MuzanyG, Johnson JL, Weer M, Bozeman L, He CM, Feng PJ, Moro R, Nara M, Nah P, Ray S, Bates E, Hae B, Nuermberger EL, Vernon A, Schluger NW; Tuberculos Trls Consortm. Substutn of rapente for ramp durg tense phase treatment of pulmonary tuberculos: study 29 of the tuberculos trls consortm. J fect D. 2012 Oct 1;206(7):1030-40. do 10.1093/fd/j461. Epub 2012 Jul 30.
Dorman SE, Sav RM, Goldberg S, Stout JE, Schluger N, MuzanyG, Johnson JL, Nah P, Hecker EJ, He CM, Bozeman L, Feng PJ, Moro RN, MacKenz W, Dooley KE, Nuermberger EL, Vernon A, Weer M; Tuberculos Trls Consortm. Day rapente for treatment of pulmonary tuberculos. A randomed, dose-rangg trl. Am J Resp Cr Care Med. 2015 Feb 1;191(3):333-43. do 10.1164/rccm.201410-1843OC. Erratum : Am J Resp Cr Care Med. 2015 May 15;191(10):1210.
Dorman SE, Nah P, Kurbatova EV, Goldberg SV, Bozeman L, Burman WJ, Chang KC, Chen M, Cotton M, Dooley KE, Engle M, Feng PJ, Fletcher CV, Ha P, He CM, Johnson JL, Lessem E, Metchock B, Mo JM, Nhung NV, Pett AC, Phls PPJ, Podany AT, Purfld AE, Robergeau K, Samaneka W, Scott NA, Semore E, Vernon A, Weer M, Swdells S, Chason RE; AS Clal Trls Group and the Tuberculos Trls Consortm. Hh-dose rapente wh or whout moxloxac for shorteng treatment of pulmonary tuberculos: Study protocol for TBTC study 31/ACTG A5349 phase 3 clal trl. Contemp Cl Trls. 2020 Mar;90:105938. do 10.1016/j.cct.2020.105938. Epub 2020 Jan 22.
Dorman SE, Nah P, Kurbatova EV, Phls PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hak J, Johnson JL, Lourens M, Martson NA, MuzanyG, Narunsky K, Nerette S, Nguyen NV, Pham TH, Prre S, Purfld AE, Samaneka W, Sav RM, Sanne Scott NA, Shenje J, Semore E, Vernon A, Waja Z, Weer M, Swdells S, Chason RE; AS Clal Trls Group; Tuberculos Trls Consortm. Four-Month Rapente Regens wh or whout Moxloxac for Tuberculos. N Engl J Med. 2021 May 6;384(18):1705-1718. do 10.1056/NEJMoa2033400.
Dossg M, Wcke JT, Askgaard DS, Nybo B. Ler jury durg antuberculos treatment: an 11-year study. Tuber Lung D. 1996 Aug;77(4):335-40. do 10.1016/s0962-8479(96)90098-2.
Ellard GA. Absorptn, metabolm and excretn of pyrazame man. Tubercle. 1969 Jun;50(2):144-58. do 10.1016/0041-3879(69)90020-8. No abstract avaable.
Ellard GA. The potentl clal snance of the onz acetylator phenotype the treatment of pulmonary tuberculos. Tubercle. 1984 Sep;65(3):211-27. do 10.1016/0041-3879(84)90079-5. No abstract avaable.
Ellard GA, Humphrs MJ, Gabrl M, Teoh R. Penetratn of pyrazame to the cerebrospal flu tuberculous meng. Br Med J (Cl Res Ed). 1987 Jan 31;294(6567):284-5. do 10.1136/bmj.294.6567.284. No abstract avaable.
Food and Drug Admtratn (FDA). Guance on General Clal Pharmacology Conseratns for Pedtr Studs for Drugs and Blogal Products: Guance for dustry (draft guance) December 2014. [Avaable from: https://www.fda.gov/med/90358/downloadTest.]
Glesp SH, Crook AM, McHugh TD, Mendel CM, Meredh SK, Murray SR, Pappas F, Phls PP, Nunn AJ; REMoxTB Consortm. Four-month moxloxac-based regens for drug-sense tuberculos. N Engl J Med. 2014 Oct 23;371(17):1577-87. do 10.1056/NEJMoa1407426. Epub 2014 Sep 7.
Grsel R, Hl A, Metjes G, Maartens G. Standard versus double dose dolutegrav patnts wh H-assocted tuberculos: a phase 2 non-comparate randomed controlled (RADNT-TB) trl. Wellcome Open Res. 2021 Jan 11;6:1. do 10.12688/wellcomeopenres.16473.1. eCollectn 2021.
Grsel R, Zhao Y, Smons B, Omar Z, Wsner L, Keene CM, Hl AM, Metjes G, Maartens G. Standard-dose versus double-dose dolutegrav H-assocted tuberculos South Afra (RADNT-TB): a phase 2, non-comparate, randomed controlled trl. Lancet H. 2023 Jul;10(7):e433-e441. do 10.1016/S2352-3018(23)00081-4. Epub 2023 May 22.
Hma JE, Radtke KK, Dorman SE, JdanA, Dooley KE, Weer M, Mcleron HM, Sav RM. Rapente Populatn Pharmacokets and Dosg Recommendatns for Latent Tuberculos fectn. Am J Resp Cr Care Med. 2020 Sep 15;202(6):866-877. do 10.1164/rccm.201912-2489OC.
Hsu AJ, Tamma PD. The Johns Hopks Hospal Antts Gueles 2023-2024. Treatment recommendatns for hospaled chdren. 2022 Johns Hopks Mede. Webse: https://tranet.sehopksmede.org/asp/pedtr.htmlTest. Last ved on: October 9th, 2023.
perl MZ, Luetkenmeyer A, Dawson R, et al; the ACTG A5372 Protocol Team. DTG PK People Wh H Receg Day 1HP For Latent TB Treatment (ACTG A5372). CRO Conference on Retrovuses and Opportunt fectns, 2022, Feb 15. Abstract 78.
JdanA, Harron TS, Nunn AJ, Phls PP, Churchyard GJ, Charalambous S, Hatherl M, Geldenhuys H, Mcleron HM, Zvada SP, Mungofa S, Shah NA, Zhou S, Magweta L, Shepherd J, Nyenda S, van Dk JH, Cloutg HE, Coleman D, Bateson AL, McHugh TD, Butcher PD, Mchon DA; RAQU Trl Team. Hh-dose rapente wh moxloxac for pulmonary tuberculos. N Engl J Med. 2014 Oct 23;371(17):1599-608. do 10.1056/NEJMoa1314210.
Kay L, Kampmann JP, Svendsen TL, Vergman B, Hansen JE, Skovsted L, Krtensen M. fluence of ramp and onz on the kets of phenyto. Br J Cl Pharmacol. 1985 Oct;20(4):323-6. do 10.1111/j.1365-2125.1985.tb05071.x.
Kjellsson MC, V LE, Goh A, Weer D, Low KM, Kern S, PlaG, Barry CE 3rd, Darto V. Pharmacoket evaluatn of the penetratn of antuberculos agents rabb pulmonary lesns. Antrob Agents Chemother. 2012 Jan;56(1):446-57. do 10.1128/AAC.05208-11. Epub 2011 Oct 10.
Kohno S, Koga H, Kaku M, MaesakS, Hara K. Prospecte comparate study of ofloxac or ethambutol for the treatment of pulmonary tuberculos. Chest. 1992 Dec;102(6):1815-8. do 10.1378/chest.102.6.1815.
Lacro C, Tranvouez JL, Phan Hoang T, Duwoos H, Lafont O. Pharmacokets of pyrazame and s metaboles patnts wh hepat crhot suffncy. Arznetelforschung. 1990 Jan;40(1):76-9.
Mathad JS, Queoz ATL, Bhosale R, Alexander M, Na S, KulkarnV, Andrade BB, Gupta A. Transcrtnal Analys for Tuberculos Pregnant Women From the PRegnancy Assocted Changes Tuberculos munology (PRACH Study. Cl fect D. 2022 Dec 19;75(12):2239-2242. do 10.1093/c/cc437.
Merle CS, Fldg K, Sow OB, Gnafon M, Lo MB, Mthane T, Odhmbo J, Amukoye E, Bah B, Kassa F, N'Dye A, Rustomjee R, de Jong BC, Horton J, Perronne C, Sman C, Lapujade O, Ollro PL, Lnhardt C; OFLOTUB/Gatloxac for Tuberculos Project. A four-month gatloxac-contag regen for treatg tuberculos. N Engl J Med. 2014 Oct 23;371(17):1588-98. do 10.1056/NEJMoa1315817. Erratum : N Engl J Med. 2015 Apr 23;372(17):1677.
Moro RN, Scott NA, Vernon A, Tepper NK, Goldberg SV, Schwartzman K, Leung CC, Schluger NW, Belknap RW, Chason RE, Nara M, Machado ES, Lopez M, Sanchez J, Vlaro ME, Sterlg TR. Exposure to Latent Tuberculos Treatment durg Pregnancy. The PREVENT TB and the dhere Trls. Ann Am Thorac Soc. 2018 May;15(5):570-580. do 10.1513/AnnalsATS.201704-326OC.
Ormerod LP, Horsfld N. Frequency and type of reactns to antuberculos drugs: observatns route treatment. Tuber Lung D. 1996 Feb;77(1):37-42. do 10.1016/s0962-8479(96)90073-8.
Bemer-Melchr P, Bryskr A, Drugeon HB. Comparon of the vro acts of rapente and ramp agast Mycobacterm tuberculos complex. J Antrob Chemother. 2000 Oct;46(4):571-6. do 10.1093/jac/46.4.571.
Patel AM, McKeon J. Avoance and management of adverse reactns to antuberculos drugs. Drug Saf. 1995 Jan;12(1):1-25. do 10.2165/00002018-199512010-00001.
Patel K, Goldman JL. Safety Concerns Surroundg Quolone Use Chdren. J Cl Pharmacol. 2016 Sep;56(9):1060-75. do 10.1002/jcph.715. Epub 2016 Mar 28.
Peloqu CA, Namdar R, Dodge AA, N DE. Pharmacokets of onz under fastg condns, wh food, and wh antacs. t J Tuberc Lung D. 1999 Aug;3(8):703-10.
Prfte C, Royer RJ. Tendon dorders wh fluoroquolones. Therap. 1996 Jul-Aug;51(4):419-20. No abstract avaable.
Preaux B, Darto V, Staab D, Weer DM, Goh A, V LE, Barry CE 3rd, StoecklM. Hh-sensy MALDMRM-MS agg of moxloxac dtrutn tuberculos-fected rabb lungs and granulomatous lesns. Anal Chem. 2011 Mar 15;83(6):2112-8. do 10.1021/ac1029049. Epub 2011 Feb 18.
Prt package sert. Natnal stute of Allergy and fectus Deases. (2021, July). Rapente (Prt) Prescrg formatn. Natnal stute of Allergy and fectus Deases.https://rsc.n.n.gov/ses/default/fes/Rapente%20%28Prt%29%20Pdated%20July%202021.pdfTest
Radtke KK, Hesselg AC, Wckler JL, Draper HR, Solans BP, Thee S, Wsner L, van der Laan LE, Four B, Nlsen J, Schaaf HS, Sav RM, Garc-Prats AJ. Moxloxac Pharmacokets, Cardc Safety, and Dosg for the Treatment of Ramp-Restant Tuberculos Chdren. Cl fect D. 2022 Apr 28;74(8):1372-1381. do 10.1093/c/cb641.
Reves R, He CM, Tapy JM, Bozeman L, Kyle RP, Hamton CD, Bock N, Nara M, Wg D, Hershfld E, Goldberg SV; Tuberculos Trls Consortm. termtent tuberculos treatment for patnts wh onz tolerance or drug restance. t J Tuberc Lung D. 2014 May;18(5):571-80. do 10.5588/tld.13.0304.
Rosenthal , Zhang M, Wlms KN, Peloqu CA, TyagS, Vernon AA, BhaWR, Chason RE, Grosset JH, Nuermberger EL. Day dosg of rapente cures tuberculos three months or less the mure model. PLoS Med. 2007 Dec;4(12):e344. do 10.1371/journal.pmed.0040344.
Rosenthal , Zhang M, Almea D, Grosset JH, Nuermberger EL. onz or moxloxac rapente-based regens for experental tuberculos? Am J Resp Cr Care Med. 2008 Nov 1;178(9):989-93. do 10.1164/rccm.200807-1029OC. Epub 2008 Aug 21.
Rosenthal , Tasneen R, Peloqu CA, Zhang M, Almea D, MdlulKE, Karakous PC, Grosset JH, Nuermberger EL. Dose-rangg comparon of ramp and rapente two pathologally dtct mure models of tuberculos. Antrob Agents Chemother. 2012 Aug;56(8):4331-40. do 10.1128/AAC.00912-12. Epub 2012 Jun 4.
Rustomjee R, Lnhardt C, Kanyok T, Davs GR, Lev J, Mthane T, Reddy C, Sturm AW, Sgel FA, Allen J, Coleman DJ, Four B, Mchon DA; Gatloxac for TB (OFLOTUB) study team. A Phase study of the sterg acts of ofloxac, gatloxac and moxloxac pulmonary tuberculos. t J Tuberc Lung D. 2008 Feb;12(2):128-38.
Sanof Rad [ramp] package sert. Sanof 2023, February. URL:https://products.sanofus/rad/rad.pdfTest.
Schaberg T, Rebhan K, Lode H. Rk factors for se-effects of onz, ramp and pyrazame patnts hospaled for pulmonary tuberculos. Eur Resp J. 1996 Oct;9(10):2026-30. do 10.1183/09031936.96.09102026.
Seddon JA, Garc-Prats AJ, Purchase SE, Osman M, Demers AM, Hoddott G, Crook AM, Owen-Powell E, Thomason MJ, Turkova A, Gb DM, Fal L, Martson N, Schaaf HS, Hesselg AC. Levofloxac versus placebo for the preventn of tuberculos dease chd contacts of multrug-restant tuberculos: study protocol for a phase cluster randomed controlled trl (TB-CHAMP). Trls. 2018 Dec 20;19(1):693. do 10.1186/s13063-018-3070-0.
Segev S, Yan Haverstock D, Rehart H. Safety of long-term therapy wh crofloxac: data analys of controlled clal trls and revw. Cl fect D. 1999 Feb;28(2):299-308. do 10.1086/515132.
Sner DE Jr. Pyroxe supplementatn durg onz therapy. Tubercle. 1980 Dec;61(4):191-6. do 10.1016/0041-3879(80)90038-0.
Turkova A, Wls GH, Wobudeya E, Chabala C, Palmer M, Kar A, Hsar S, Choo L, Musoke P, Mulenga V, Mave V, Joseph B, LeBeau K, Thomason MJ, MboRB, Kapasa M, van der Zalm MM, Rahur P, BhavanPK, Mcleron H, Demers AM, Aarnoutse R, Love-Koh J, Seddon JA, Welch SB, Graham SM, Hesselg AC, Gb DM, Crook AM; SHE Trl Team. Shorter Treatment for Nonsevere Tuberculos Afran and dn Chdren. N Engl J Med. 2022 Mar 10;386(10):911-922. do 10.1056/NEJMoa2104535.
Turkova A, Waalewn H, Chan MK, Bollen PDJ, Bwakura-DangarembMF, Keknwa AR, Cotton MF, Lugemwa A, Varva E, Ahbwe GM, Srompotong U, Mumbo V, Amuge P, Zuewd P, AlS, Kyo CM, Archary M, Ferrand RA, VlarA, Gb DM, Burger DM, Ford D, Colbers A; ODYSSEY Trl Team. Dolutegrav twe-day dosg chdren wh H-assocted tuberculos: a pharmacoket and safety study wh the open-label, multentre, randomed, non-ferry ODYSSEY trl. Lancet H. 2022 Sep;9(9):e627-e637. do 10.1016/S2352-3018(22)00160-6. Epub 2022 Jul 19.
UNAS. (2022, March 24). Fact Sheet - Tuberculos (TB) and H. https://www.unas.org/ses/default/fes/med_asset/20220324_TB_FactSheet_en.pdfTest
Weer M, Sav RM, Kenz WR, Wg D, Peloqu CA, Engle M, Blen E, Proda TJ, Gelfond JA, Scott NA, Abdel-Rahman SM, Kearns GL, Burman WJ, Sterlg TR, Vlaro ME; Tuberculos Trls Consortm PREVENT TB Pharmacoket Group. Rapente Pharmacokets and Toleraby Chdren and Adults Treated Once Weekly Wh Rapente and onz for Latent Tuberculos fectn. J Pedtr fect D Soc. 2014 Jun;3(2):132-45. do 10.1093/jps/p077. Epub 2014 Jan 16.
Wlmson B, Dooley KE, Zhang Y, Back DJ, Owen A. ductn of flux and efflux transporters and cytochrome P450 3A4 prary human hepatocytes by ramp, rabut, and rapente. Antrob Agents Chemother. 2013 Dec;57(12):6366-9. do 10.1128/AAC.01124-13. Epub 2013 Sep 23.
Wth S, Em SGS, Engel A, Dtyar V, Crllo M, DasolC, Stass H, Wlmann S, Nkulka R, Grossmann U; MOXED Study Group. Moxloxac Pedtr Patnts Wh Complated tra-abdomal fectns: Results of the MOXED Randomed Controlled Study. Pedtr fect D J. 2018 Aug;37(8):e207-e213. do 10.1097/F.0000000000001910.
World Health Organatn, Global Tuberculos Programme, Maternal, Newborn, Chd & Adolescent Health & Ageg (2006). Ethambutol effacy and toxy: lerature revw and recommendatns for day and termtent dosage chdren. WHO/HTM/TB/2006.365, WHO/FCH/CAH/2006.3.
World Health Organatn (WHO), and UNA. Toolk for research and development of paedtr antetroval drugs and formulatns. Geneva: World Health Organatn; 2018. Lense: CC BY-NC-SA 3.0 O. URL: https://.who.t/bstream/handle/10665/273151/9789241514361-eng.pdf?sequence=1Test
World Health Organatn (2022a) WHO Global Tuberculos Report 2022. Global Tuberculos Programme, Tuberculos Vacce Accelerator Counc. October, 2022. BN: 978-92-4-006172-9.
WHO consolated gueles on tuberculos: Module 4: Treatment - Drug-susceptle tuberculos treatment [ternet]. Geneva: World Health Organatn; 2022. Avaable from http://www.ncbnlm.n.gov/books/NBK581329Test/
WHO consolated gueles on tuberculos: Module 5: Management of tuberculos chdren and adolescents [ternet]. Geneva: World Health Organatn; 2022. Avaable from http://www.ncbnlm.n.gov/books/NBK579387Test/
World Health Organatn (2022). Growth reference data for 5-19 years. [Apr 19, 2022]. Avaable from: https://www.who.t/tools/growth-reference-data-for-5to19-yearsTest.
World Health Organatn (2022). Chd growth standards. [Apr 19, 2022]. Avaable from: https://www.who.t/tools/chd-growth-standardsTest.
World Health Organatn (2022f). Global Tuberculos Report 2022; 3.3 TB treatment and treatment coverage. https://www.who.t/teams/global-tuberculos-programme/tb-reports/global-tuberculos-report-2022/tb-dgnos-treatment/3-3-tb-treatment-and-treatment-coverageTest. Last ved: November 1, 2023.
Yee D, Valuette C, Pelletr M, Parn Rocher Menzs D. cence of serus se effects from fst-le antuberculos drugs among patnts treated for acte tuberculos. Am J Resp Cr Care Med. 2003 Jun 1;167(11):1472-7. do 10.1164/rccm.200206-626OC. Epub 2003 Jan 31.
Zent C, Smh P. Study of the effect of concomant food on the bavaaby of ramp, onz and pyrazame. Tuber Lung D. 1995 Apr;76(2):109-13. do 10.1016/0962-8479(95)90551-0.
Zhang T, LSY, Wlms KN, Andrs K, Nuermberger EL. Short-course chemotherapy wh TMC207 and rapente a mure model of latent tuberculos fectn. Am J Resp Cr Care Med. 2011 Sep 15;184(6):732-7. do 10.1164/rccm.201103-0397OC. Epub 2011 Jun 9.
ZrskM, Bek E. Se-effects of drug regens used short-course chemotherapy for pulmonary tuberculos. A controlled clal study. Tubercle. 1980 Mar;61(1):41-9. do 10.1016/0041-3879(80)90060-4.
Zvada SP, Van Der Walt JS, Smh PJ, Four PB, Roscno G, Mchon D, Sonsson US, Mcleron HM. Effects of four dferent meal types on the populatn pharmacokets of sgle-dose rapente healthy male volunteers. Antrob Agents Chemother. 2010 Aug;54(8):3390-4. do 10.1128/AAC.00345-10. Epub 2010 Jun 1.
Shortened Regimen for Drug-susceptible TB in Children

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06253715Test

المساهمون: Fahad Javed Awan, Doctor

المصدر: Role of Low Dose Steroids vs Placebo in Addition to Anti-tuberculosis Treatment (ATT) in Regression of Lymph Node Sizes in Patients With Tuberculous Lymphadenopathy

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06236152Test

المصدر: Chen YL, Kuo YW, Wu HD, Wang JY, Wang HC. The applatn of ultrasound shear wave elastography the predtn of paradoxal upgradg reactn tuberculous lymphaden. a pot study. J Formos Med Assoc. 2022 Sep;121(9):1696-1704. do 10.1016/j.jfma.2021.12.002. Epub 2021 Dec 23.
Kuo YW, Chen YL, Wu HD, Chn YC, Huang CK, Wang HC. Applatn of transthorac shear-wave ultrasound elastography lung lesns. Eur Resp J. 2021 Mar 25;57(3):2002347. do 10.1183/13993003.02347-2020. Prt 2021 Mar.
Application of Ultrasound Shear Wave Elastography on the Adjunct Corticosteroid Therapy on Tuberculous Lymphadenitis: a Randomized Control Trial

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05861440Test

المؤلفون: Indonesia's Ministry of Research and Technology (Ristekdikti/BRIN)

المساهمون: Bernadette Dian Novita, MD.,PhD, MD.,PhD

المصدر: Immunology Dysregulation in Lymphadenitis Tuberculosis : An Observational Study Using Patient' Block Paraffins 2019 Until 2021

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05202548Test

المساهمون: Chao-Chi Ho

المصدر: Diagnosis of Mediastinal Tuberculous Lymphadenopathy by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA)

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT01121432Test

المصدر: Evaluation of Positron Emission Tomography in Extrapulmonary Tuberculosis

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT01613196Test